Back

GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Association of Neurology

Paris, France, April 20, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that an abstract was accepted for an oral presentation at the 2017 Annual Meeting of the American Association of Neurology (AAN) in Boston, MA, April 22-28, 2017.

Please find the full PDF press release attached.  gensight_biologics_pr_2017_aan_20170420

 

Contacts

GenSight Biologics
Thomas Gidoin
Chief Financial Officer
moc.s1511447655cigol1511447655oib-t1511447655hgisn1511447655eg@ri1511447655
+33 (0)1 76 21 72 20
NewCap
I
nvestor Relations
Florent Alba
ue.pa1511447655cwen@1511447655thgis1511447655neg1511447655
+33 (0)1 44 71 98 55
Rooney Partners
Media Relations
Marion Janic
moc.o1511447655cyeno1511447655or@ci1511447655najm1511447655
+1-212-223-4017

Source: Gensight